NDRG3

Across TCGA pan-cancer cohorts, NDRG3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NDRG3 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher NDRG3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NDRG3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BLCA, COAD, and UCEC are the cancer types where NDRG3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	DFS	Median	III,IV	0.152	0.574	.001	15	view →
COAD	OS	Median	II,III,IV	0.464	0.853	.005	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.444	.035	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
SKCM	DFS	Median	II,III,IV	1.000	0.669	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NDRG3–BLCA (DFS)

Open the BLCA breakdown →